MEMORANDUM OPINION

TIMOTHY J. KELLY, District Judge.

Plaintiff Rev. Ryan "Sasha" Gallagher, proceeding pro se, sues the Food and Drug Administration (FDA) and Dr. Stephen D. Hardeman, a senior official at its Center for Drug Evaluation and Research. Before the Court is Defendants' motion to dismiss. Because Gallagher's complaint does not include a short and plain statement showing why he is entitled to relief, the Court will grant the motion and dismiss the case without prejudice for failure to comply with Federal Rule of Civil Procedure 8(a).

* * *

Pleadings prepared by pro se litigants are held to less stringent standards than those that apply to pleadings prepared by lawyers. See Haines v. Kerner, 404 U.S. 519, 520 (1972). However, pro se litigants must follow the Federal Rules of Civil Procedure. Jarrell v. Tisch, 656 F.Supp. 237, 239 (D.D.C. 1987). Rule 8(a) requires a complaint to include "a short and plain statement of the claim showing that the pleader is entitled to relief." Fed. R. Civ. P. 8(a). "The purpose of the rule is to give fair notice of the claim being asserted so as to permit the adverse party the opportunity to file a responsive answer, prepare an adequate defense and determine whether the doctrine of res judicata is applicable." Brown v. Califano, 75 F.R.D. 497, 498 (D.D.C. 1977). "Where a complaint is insufficiently focused, it places an undue burden on the defendant to answer or move and it invites unnecessary delay and confusion in the proceedings." Achagzai v. Broad. Bd. of Governors, 109 F.Supp.3d 67, 71 (D.D.C. 2015).

* * *

Even liberally construed, Gallagher's complaint and his subsequent pleadings do not contain a short and plain statement explaining why he is entitled to relief.1 Gallagher's complaint focuses on the substance 4-Hydroxy-N-methyl-N-isopropyltryptamine ("4-OH-MiPT"). According to Gallagher, it is central to his religious beliefs:

ECF No. 1 ("Compl.") at 2. Gallagher alleges that he wrote to the FDA about "a Religious Exemption for 4-OH-MiPT use within the practices of the Shaivite Temple." Id. at 1. Hardeman responded. Id. at 4. The FDA interpreted Gallagher's letter as a request for an exemption from the requirement to submit an Investigational New Drug Application (IND) to conduct a clinical investigation of 4-OH-MiPT. Id.; see also 21 C.F.R. § 312.2(b). Hardeman listed the requirements for an exemption, but informed Gallagher that he did not appear to qualify for one. Compl. at 4. Hardeman informed Gallagher that, as a result, he would have to submit an IND if he wished to conduct a clinical investigation of 4-OH-MiPT. Id. Gallagher further alleges that Hardeman told him in a later email that the FDA "does not consider Religiousity [sic] when evaluating the safety of proposed clinical experimentation on Humans." Id. at 2.

In his complaint, Gallagher alleges that the FDA's "IND program is in violation of the First Amendment," and cites a case in which the D.C. Circuit held that the Drug Enforcement Administration (DEA) was not required to provide a religious-use exemption from federal laws proscribing marijuana. Id. at 2 (citing Olsen v. Drug Enf't Admin., 878 F.2d 1458 (D.C. Cir. 1989). He also asserts that "they are refusing to create processes similar to the DEA's" and cites a case in which the Supreme Court held that the Department of Justice had not shown, under the Religious Freedom Restoration Act (RFRA), 42 U.S.C. § 2000bb-1 et seq., a compelling interest in barring a religious sect's sacramental use of a substance regulated under Schedule I of the Controlled Substances Act (CSA), 21 U.S.C. § 812(c). Id. at 3 (citing Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal, 546 U.S. 418 (2006)).

The complaint also includes several unexplained references to marijuana. For example, Gallagher references "Federal Marijuana Patients, [sic] and GW Pharma THCv," and says he told Hardeman that "[w]e consider THCv to be the non-Marijuana form of Lord Shiva." Id. at 1. And he alleges that "Synthetic THCv is not Scheduled" and cites a case from outside this Circuit holding that "the DEA's relevant rules and regulations may be enforced only insofar as they ban the presence of marijuana or synthetic THC." Id. at 7 (quoting Hemp Indus. Ass'n. v. Drug Enf't Admin., 357 F.3d 1012, 1013 (9th Cir. 2004)). But he never explains how marijuana or THC bear on the instant case.2

These allegations in the complaint do not constitute "a short and plain statement of the claim" showing that Gallagher "is entitled to relief." Fed. R. Civ. P. 8(a). An IND is the start of the process through which pharmaceutical drug sponsors seek FDA approval to test proposed new pharmaceutical drugs for safety and efficacy, before they are approved for sale and marketing. See 21 U.S.C. § 355(i); 21 C.F.R. § 312.1. But Gallagher does not allege that he seeks to test, sell, or market a pharmaceutical drug. See generally Compl. Nor does he allege that his intended use of 4-OH-MiPT—whatever that may be—would cause that substance to be subject to the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. § 301, et seq. See 21 U.S.C. § 321(g)(1) (defining the term "drug").3 In sum, he does not explain how the "IND program" or any part of the FDCA even applies to him, let alone violates his First Amendment rights or burdens the practice of his religion.4

Gallagher's subsequent filings only further muddy the waters, as he appears to shift the basis for his claim away from the allegations in the complaint. In his Opposition, he reiterates that "our Temple, the Shaivite Temple, believes that 4-OH-MiPT, Miprocin, is a Soma, a Sacred Drink, a Sacred Substance, used by and given to us by the Gods." ECF No. 15 at 1. He requests, with more specificity than in the complaint, that he "be allowed to Manufacture and Transport this NON-SCHEDULED SUBSTANCE" and that he "be able to use it in Ritual and Ceremony." Id. And he suggests that he is barred from doing so under the Controlled Substance Analogue Enforcement Act ("Analogue Act"), see 21 U.S.C. § 813, because "the FDA and DEA are treating 4-OH-MiPT, Miprocin, when ingested by Humans, as if it is a Schedule I substance." Id. But once again, Gallagher does not allege that he seeks to test, sell, or market a pharmaceutical drug such that he would need an IND, the focus of his complaint and the letter he received from Defendants. Moreover, he does not plead facts that suggest that the government is, in fact, treating 4-OH-MiPT as a Schedule I substance. And even assuming it is, this allegation hardly clarifies his claim—because he also asserts that the FDA informed him that the Analogue Act "has no bearing on the applicability of" an IND exemption. See Compl. at 2. As Defendants point out, "[t]he laws regulating scheduled substances are separate and distinct from the new drug provisions of the FDCA."5 ECF No. 12 at 4.

Finally, in a subsequent "Motion to Deny Defendant," Gallagher argues—for the first time—that "this is an Administrative Procedure Act (APA) case, regarding the FDA." ECF No. 20 at 1. But he does not identify any allegedly unlawful final agency action that caused him harm. See 5 U.S.C. § 704.6

* * *

As explained above, nowhere in Gallagher's complaint or subsequent pleadings does he provide a short and plain statement of why he is entitled to relief. Therefore, he has failed to comply with Rule 8(a). Accordingly, the Court will grant Defendants' motion and dismiss the case without prejudice. A separate order will issue.